ProCE Banner Activity

Prognostic Marker Testing in Treatment-Naive Patients With CLL—Still Important

Clinical Thought

Why testing for TP53, del(17q), and IGHV status critical for treatment selection and outcome optimization. Here’s my take.

Released: September 22, 2020

Expiration: September 21, 2021

Share

Faculty

Danielle M. Brander

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Danielle M. Brander, MD

Medical Instructor
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine
Duke University
Attending Physician, Hematologic Malignancies
Duke University Health System
Durham, North Carolina

Danielle M. Brander, MD, has disclosed that she has received consulting fees from AbbVie, ArQule, AstraZeneca, Genentech, Pharmacyclics, Pfizer, Teva, TG Therapeutics, and Verastem and funds for research support paid to her institution from AbbVie; ArQule; Ascentage; AstraZeneca; BeiGene; DTRM; Genentech; Juno Therapeutics, a Bristol-Myers Squibb company; MEI Pharma; Pharmacyclics; TG Therapeutics; Tolero; and Verastem.